on november 9, 2020, pfizer announced that bnt162 was 90% effective at preventing people from catching covid-19. they asked the fda to approve the vaccine for emergency use. the company had not yet published the results of the study in a formal scientific paper, so the fda said they needed time to look at the results for themselves.